Advanced Filters
noise

solid-tumors Clinical Trials

A listing of solid-tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,625 clinical trials
H Herui Yao

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

18 years of age All Phase 1

Study of ZGGS34 in Participants With Advanced Solid Tumors

This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion phase to assess the efficacy and …

18 - 75 years of age All Phase 1/2
J Jingdong Zhang, Postdoctor

A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects

This study is an open, multicenter, Phase I/II clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.

18 - 75 years of age All Phase 1/2
T Tangfeng Hospital

Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of functionally enhanced ALPP-targeted engineered T Cells (Herein referred to as Enhanced ALPP CAR-T) in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is …

18 - 70 years of age All Phase 0
S Shun Lu, Ph.D

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.

18 - 75 years of age All Phase 1/2
M Melissa Hines, MD

Indocyanine Green (ICG) Guided Tumor Resection

This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure. An optimal intra-operative tool to help visualize tumor and its margins would be of …

years of age All Phase 1
S Site Public Contact

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

6 - 30 years of age All Phase 1/2
W Weidong Han, Ph.D

PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor

In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with late-stage advanced solid tumors . A total of 20 to 30 patients are planned to be enrolled and receive PIN plus …

18 - 75 years of age All Phase 1
W Wenbin Li

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.

18 years of age All Phase 1

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.

12 - 18 years of age All Phase 1

Simplify language using AI